Details
Stereochemistry | RACEMIC |
Molecular Formula | C22H28ClNO.ClH |
Molecular Weight | 394.378 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(OCCN1CCCCCC1)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3
InChI
InChIKey=YFCVXQAEHQJKQG-UHFFFAOYSA-N
InChI=1S/C22H28ClNO.ClH/c1-22(19-9-5-4-6-10-19,20-11-13-21(23)14-12-20)25-18-17-24-15-7-2-3-8-16-24;/h4-6,9-14H,2-3,7-8,15-18H2,1H3;1H
Setastine (Loderix) is a potent antagonist of histamine H1-receptor mediated responses. Setastine inhibits anaphylactic shock in guinea-pigs sensitized by horse serum. No antiserotonin, anticholinergic and antiadrenergic effect of the compound can be detected. Setastine has a long lasting (up to 16 h) antihistamine effect with a good oral effectiveness. It shows no cardiovascular effects in cats. Setastine shows a much weaker CNS depressant activity than clemestine fumarate. In displacement studies (3H-mepyramine) setastine had significantly weaker affinity for the central nervous system (CNS) H1-receptors than clemastine fumarate. It is concluded that setastine is a non-sedative highly active H1-antagonist.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1982751
Curator's Comment: Setastine shows a much weaker CNS depressant activity than clemestine fumarate. In displacement studies (3H-mepyramine) setastine had significantly weaker affinity for the central nervous system (CNS) H1-receptors than clemastine fumarate. It is concluded that setastine is a non-sedative highly active H1-antagonist.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2890137 | https://patents.google.com/patent/CN102417489B
Curator's Comment: Setastine as a new generation of allergy medications first successfully developed by Hungarian company Egis Pharmaceuticals Ltd and first marketed in Hungary in 1987.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3573 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1982751 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2890137
For prolonged use a dose of 2 mg three times/day (t.i.d.) is recommended. The antihistaminic effect of setastine almost equalled that of clemastine given in a dose of 1 mg t.i.d.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2455987
At low concentrations Setastine (Loderix) preincubated with rat peritoneal mast cells for 10 min prior to the addition of various stimulants (immune aggregates, ionophore A23187 and compound 48/80) produced a concentration-dependent inhibition of histamine release, while at high concentrations it induced the release of histamine. The IC50 values were calculated as 0.2, 15 and 50 uM by using immune aggregate, (rat IgG2 alpha + anti rat IgG) calcium ionophore and 48/80 as stimulants, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID90975177
Created by
admin on Sat Dec 16 08:21:42 GMT 2023 , Edited by admin on Sat Dec 16 08:21:42 GMT 2023
|
PRIMARY | |||
|
m9881
Created by
admin on Sat Dec 16 08:21:42 GMT 2023 , Edited by admin on Sat Dec 16 08:21:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
43081
Created by
admin on Sat Dec 16 08:21:42 GMT 2023 , Edited by admin on Sat Dec 16 08:21:42 GMT 2023
|
PRIMARY | |||
|
100000078435
Created by
admin on Sat Dec 16 08:21:42 GMT 2023 , Edited by admin on Sat Dec 16 08:21:42 GMT 2023
|
PRIMARY | |||
|
SUB15235MIG
Created by
admin on Sat Dec 16 08:21:42 GMT 2023 , Edited by admin on Sat Dec 16 08:21:42 GMT 2023
|
PRIMARY | |||
|
T2MB6P84ON
Created by
admin on Sat Dec 16 08:21:42 GMT 2023 , Edited by admin on Sat Dec 16 08:21:42 GMT 2023
|
PRIMARY | |||
|
59767-13-4
Created by
admin on Sat Dec 16 08:21:42 GMT 2023 , Edited by admin on Sat Dec 16 08:21:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD